2025-01-21 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Relative to S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the period analyzed, MRK's cumulative return (61.66%) significantly lagged behind the S&P 500's (VOO) return (118.37%). The difference is -56.7%, placing it at the 6.3rd percentile of the historical range of underperformance relative to the S&P 500. This indicates MRK's underperformance relative to the broader market.  The provided alpha consistently shows negative values (-0.1), further supporting this underperformance against the benchmark.  Beta values are fairly consistent around 0.1, indicating lower volatility than the market, although this is consistent across all time periods, indicating less of a market hedge than one might expect.

**2. Recent Price Movement:**

* **Closing Price:** $97.92
* **5-day Moving Average:** $99.87
* **20-day Moving Average:** $99.48
* **60-day Moving Average:** $100.25

The recent closing price is below all three moving averages, suggesting a downward trend in the short-term.  The price has fallen from $100.7 the previous day, representing a substantial drop, potentially indicating a short-term bearish sentiment.

**3. Technical Indicators and Expected Return:**

* **RSI:** 42.77 (Below 50, suggesting the stock is currently in oversold territory)
* **PPO:** 0.0132 (Positive, but very close to zero suggesting weak momentum)
* **20-Day Relative Divergence:** -7.5% (Indicates a recent short-term decline)
* **Expected Return (2+ years):** 96.5% (This is significantly higher than the historical performance and should be treated cautiously.  It is crucial to understand the assumptions behind this expected return.)
The substantial daily price drop (-2.76%) signifies a potential short-term bearish trend or a short-term correction. The combination of RSI, PPO, and relative divergence points toward a bearish outlook.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-11-06 | $1.25  | $16.66B       |
| 2024-08-05 | $2.15  | $16.11B       |
| 2024-05-03 | $1.88  | $15.78B       |
| 2023-11-03 | $1.87  | $15.96B       |
| 2024-11-06 | $1.87  | $15.96B       |

There appears to be a duplicate entry for November 2024. Assuming this is an error, the data shows some volatility in EPS, with a noticeable drop in the most recent quarter. Revenue remains relatively consistent, showing moderate growth in recent quarters.  Further investigation would be needed to determine the reasons for EPS fluctuations.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |
| 2023-09-30 | $15.96B   | 73.29%        |

Revenue shows a generally upward trend, although there's slight variability.  Profit margins are high and generally consistent, albeit with a small dip in Q4 2023.

**Capital and Profitability:**

| Quarter    | Equity     | ROE           |
|------------|------------|---------------|
| 2024-09-30 | $44.50B   | 7.09%         |
| 2024-06-30 | $43.58B   | 12.52%        |
| 2024-03-31 | $40.36B   | 11.80%        |
| 2023-12-31 | $37.58B   | -3.26%        |
| 2023-09-30 | $41.25B   | 11.50%        |

Equity has generally increased, but ROE shows significant volatility, with a substantial negative value in Q4 2023. This requires further investigation to understand the underlying causes.


**7. Overall Summary:**

MRK's performance has lagged the S&P 500 significantly. While revenue and profit margins remain strong, recent earnings show some EPS volatility, and the negative ROE in Q4 2023 is a major concern requiring deeper analysis. Short-term technical indicators suggest a bearish sentiment.  The projected 2+ year return of 96.5% is exceptionally high and should be viewed with extreme caution, requiring a thorough examination of the methodology used to arrive at that figure.  The current situation warrants a closer examination of the company's specific news and financial reports to assess the reasons for the recent underperformance and the outlook for the future.  Further due diligence is essential before making any investment decisions.
